|Chronic HepB case
Oct 22, 2004
I have chronic HepB. ALT=54, AST=37, Liver Biopsy Grade 1, Fibrosis stage2, HepBeantigen positive, HepBeAntibody Positive, AFP = 3.6, Ultrasound = Normal. HBV DNA log = 8.1 HBV DNA Log in year 2002 = 8, Do I need to start the treatment? If so what treament? What is the prognosis? How long will it take to reach to end stage if untreated.
Response from Dr. McGovern
With a liver biopsy with fibrosis stage 2 I would start treatment now.
Treatment for hepatitis B has reached a great stage. We now have a variety of drugs and this is only going to improve over time with other new drugs soon ready for use.
It would be reasonable to start adefovir (Hepsera) daily which is very well tolerated and has slow to evolve resistance. Another drug is lamivudine. It is also well tolerated although resistance is a big problem. Pegasys has also been used for hepatitis B with good results but has more side effects.
The time it would take to become end-stage is difficult to predict. Everyone is different. And there is no guarantee that you would become "end-stage". Not everyone progresses. Stay away from alcohol for sure.
Get vaccinated for hepatitis A.
Chronic Hep B meds and HIV impact
- What Is The The Most Common Route Of Hiv Infection Worldwide?
- How Long Can A Person Live With Hiv And Hepatitis?
- Can You Get Hep C From Drinking Out Of A Cup Or Eating From Someone's Plate?
- Thrush On Tonsils
- Can You Get Hepatitis From Fecal Matter?
- Can A Condom Protect You From Getting Hiv?
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.